Form D · Biotechnology
Gliacure, Inc.
Boston, MA · CIK 0001543496
Offering snapshot reported Sep 4, 2018 · SEC filing
- Reported sold
- $1.58M Offering amount: $1.58M
- Investors reported
- 36 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- Aug 17, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 4, 2018 | Initial | $1,577,996 | No comparison | 36 | SEC filing |
| Aug 8, 2014 | Amendment | $5,800,026 | $2,831,149vs May 13, 2014 | 98 | SEC filing |
| May 13, 2014 | Initial | $2,968,877 | No comparison | 38 | SEC filing |
| Feb 29, 2012 | Initial | $1,000,000 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-320579
Source: Form D, filed Sep 4, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Walter Dewey | Director, Executive |
| Philip Haydon | Director, Executive |
| Yolande Haydon | Executive |
| Michael Szulczewski | Director, Executive |
| Joseph S. Zakrzewski | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
234 Causeway Street, #809
Boston, MA, 02114
Boston, MA, 02114